China Longevity (1863) Announces Ongoing Trading Suspension and Regulatory Developments

Bulletin Express
2025/10/31

China Longevity Group Company Limited (1863) announced that its production, operation, and finances remain in stable condition. The company intends to continue focusing on research and development of new materials and products.

According to the latest update, the company’s shares have been suspended from trading on the Stock Exchange since 14 February 2013. The Stock Exchange has not issued any new delisting notice to date, and previous communication indicated that it would refrain from exercising its right to delist until further notice.

The Securities and Futures Commission (SFC) remains engaged in a regulatory review related to a Show Cause Letter issued in November 2014. A Resumption Application was submitted in December 2019, and, following additional meetings in 2020 and 2021, the Commission’s Board has yet to reach a final decision. The review remains ongoing, with the Commission potentially seeking further information.

China Longevity notes that trading in its shares will remain suspended until further notice.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10